Latest news with #Qure.AI
Yahoo
04-06-2025
- Health
- Yahoo
£1 million project to test AI's effectiveness in Scottish NHS
A £1 million project is underway to test the safety and effectiveness of artificial intelligence in healthcare. Funded by Innovate UK, the scheme brings together hospitals, Glasgow and Edinburgh universities, and technology companies to create a validation framework for AI tools in the Scottish NHS. The project involves collaboration between NHS Greater Glasgow and Clyde, NHS Lothian, and AI evaluation company Aival. Read more: 'I would not be here today': Glasgow nurse's quick thinking saves colleagues life Dr Rishi Ramaesh, consultant radiologist and innovation fellow at NHS Lothian, said: "Artificial intelligence has tremendous potential to improve patient care, but healthcare leaders need confidence that these systems are safe and effective. "This project will help healthcare leaders to evaluate AI, and make sure that new technologies deliver real benefits for patients." Aival's independent evaluation platform will be used to assess AI systems for diagnosing head trauma and lung cancer, aiming to improve care for patients and support NHS staff. The platform allows hospitals to verify AI performance using anonymised patient data and provides ongoing monitoring once the software is deployed. The project will also test the Aival platform's ability to monitor long-term AI performance, addressing concerns about 'drift'—the decline in software accuracy over time due to changes in patient populations, disease trends, or equipment updates. Dr Mark Hall, consultant radiologist at NHS Greater Glasgow and Clyde, said: "Post-deployment surveillance monitoring is a critical yet often overlooked aspect of patient care, especially in radiology, where early detection of disease progression can make all the difference. "Despite its importance, there are currently no standardised guidelines. "AI-powered monitoring software bridges this gap by providing a structured approach." One of the challenges addressed by the project is the lengthy testing process for AI. Currently, it can take more than nine months to evaluate a single product, and there are more than 200 AI options available for some hospital departments. This has limited the rollout of AI solutions in clinical settings. The project will compare six commercial AI products used in stroke and lung cancer triage, including tools developed by InferVision, Annalise-AI, and Luciana D'Adderio, Edinburgh University academic and AI evaluation and assurance expert, said: "AI technology is achieving widespread deployment across healthcare settings, yet its assurance has not received the rigorous attention it demands. "There is an urgent need for innovative tools and technologies for AI assurance, which themselves must undergo thorough evaluation and validation. "This critical challenge forms the cornerstone of our groundbreaking project." Kanwal Bhati, CEO of Aival (Image: Emelie Holgersson) Read more: New general manager expected to be 'big hit' at Glasgow care home Kanwal Bhatia, chief executive officer and founder of Aival, said: "It's vital that we monitor and check AI that's being used in decisions on patients' health, to ensure the best outcomes for patients. "Any healthcare workers using AI need to be sure that the product is doing what it says it does – not just now, but five years in the future. "Putting in place effective validation systems will encourage trust and adoption of AI, and will deliver cost savings and growth in the NHS and in private healthcare. "We work hand in hand with NHS leaders, clinical and technical teams to provide the expertise and software to ensure that their AI systems are doing what they're supposed to do."
Glasgow Times
04-06-2025
- Business
- Glasgow Times
£1m project to test safety of AI in Scottish healthcare
Funded by Innovate UK, the scheme brings together hospitals, Glasgow and Edinburgh universities, and technology companies to create a validation framework for AI tools in the Scottish NHS. The project involves collaboration between NHS Greater Glasgow and Clyde, NHS Lothian, and AI evaluation company Aival. Read more: 'I would not be here today': Glasgow nurse's quick thinking saves colleagues life Dr Rishi Ramaesh, consultant radiologist and innovation fellow at NHS Lothian, said: "Artificial intelligence has tremendous potential to improve patient care, but healthcare leaders need confidence that these systems are safe and effective. "This project will help healthcare leaders to evaluate AI, and make sure that new technologies deliver real benefits for patients." Aival's independent evaluation platform will be used to assess AI systems for diagnosing head trauma and lung cancer, aiming to improve care for patients and support NHS staff. The platform allows hospitals to verify AI performance using anonymised patient data and provides ongoing monitoring once the software is deployed. The project will also test the Aival platform's ability to monitor long-term AI performance, addressing concerns about 'drift'—the decline in software accuracy over time due to changes in patient populations, disease trends, or equipment updates. Dr Mark Hall, consultant radiologist at NHS Greater Glasgow and Clyde, said: "Post-deployment surveillance monitoring is a critical yet often overlooked aspect of patient care, especially in radiology, where early detection of disease progression can make all the difference. "Despite its importance, there are currently no standardised guidelines. "AI-powered monitoring software bridges this gap by providing a structured approach." One of the challenges addressed by the project is the lengthy testing process for AI. Currently, it can take more than nine months to evaluate a single product, and there are more than 200 AI options available for some hospital departments. This has limited the rollout of AI solutions in clinical settings. The project will compare six commercial AI products used in stroke and lung cancer triage, including tools developed by InferVision, Annalise-AI, and Luciana D'Adderio, Edinburgh University academic and AI evaluation and assurance expert, said: "AI technology is achieving widespread deployment across healthcare settings, yet its assurance has not received the rigorous attention it demands. "There is an urgent need for innovative tools and technologies for AI assurance, which themselves must undergo thorough evaluation and validation. "This critical challenge forms the cornerstone of our groundbreaking project." Kanwal Bhati, CEO of Aival (Image: Emelie Holgersson) Read more: New general manager expected to be 'big hit' at Glasgow care home Kanwal Bhatia, chief executive officer and founder of Aival, said: "It's vital that we monitor and check AI that's being used in decisions on patients' health, to ensure the best outcomes for patients. "Any healthcare workers using AI need to be sure that the product is doing what it says it does – not just now, but five years in the future. "Putting in place effective validation systems will encourage trust and adoption of AI, and will deliver cost savings and growth in the NHS and in private healthcare. "We work hand in hand with NHS leaders, clinical and technical teams to provide the expertise and software to ensure that their AI systems are doing what they're supposed to do."
Daily Record
04-06-2025
- Business
- Daily Record
NHS Lothian partner in project evaluating adoption of artificial intelligence products
Testing a single piece of AI software currently takes more than nine months NHS Lothian is one of two health boards in Scotland partnering with an evaluation company to speed up the safe adoption of artificial intelligence (AI) in the healthcare system. The £1 million Innovate UK-funded project brings together NHS Lothian and NHS Greater Glasgow and Clyde hospitals, Edinburgh and Glasgow universities, and technology companies. Testing a single piece of AI software currently takes more than nine months, and with more than 200 AI products available for a single hospital department, checking all of them individually using traditional clinical trial or service evaluation models isn't realistic. The result is that very few trials turn into real-world solutions, meaning that patients, hospitals and AI developers all lose out. The collaboration will use Aival's independent evaluation platform to assess AI systems in a secure environment, with all patient data anonymised and remaining within an NHS secure environment. The project will assess the use of the Aival platform to compare six commercial AI products for the triage of stroke and lung cancer patients from AI developers InferVision, Annalise-AI and – who are all collaborating with the programme. AI products are often calibrated to the locations where they are being used to allow for differences in the local population, meaning they may not generalise to different groups without extra training. The performance of AI products changes over time – even when the product itself isn't altered. This is known as 'drift', and can happen as a patient population changes, as the commonness of a disease shifts, or a scanner's software is updated. Dr Rishi Ramaesh, Consultant Radiologist and Innovation Fellow at NHS Lothian, said: 'Artificial intelligence has tremendous potential to improve patient care, but healthcare leaders need confidence that these systems are safe and effective. This project will help healthcare leaders to evaluate AI, and make sure that new technologies deliver real benefits for patients.' Luciana D'Adderio, Edinburgh University academic and AI evaluation and assurance expert, said: 'AI technology is achieving widespread deployment across healthcare settings, yet its assurance has not received the rigorous attention it demands. 'The current frameworks for evaluation and monitoring fall short in adequately assuring AI systems, primarily because AI represents a fundamental departure from the traditional technologies these frameworks were designed to assess. 'There is an urgent need for innovative tools and technologies for AI assurance, which themselves must undergo thorough evaluation and validation. This critical challenge forms the cornerstone of our groundbreaking project.' Kanwal Bhatia, CEO and founder of Aival, said: 'It's vital that we monitor and check AI that's being used in decisions on patients' health, to ensure the best outcomes for patients. 'Any healthcare workers using AI need to be sure that the product is doing what it says it does – not just now, but five years in the future. While many NHS teams understand this, they currently lack the tools to properly evaluate the AI products. 'Putting in place effective validation systems will encourage trust and adoption of AI, and will deliver cost savings and growth in the NHS and in private healthcare. 'We work hand in hand with NHS leaders, clinical and technical teams to provide the expertise and software to ensure that their AI systems are doing what they're supposed to do.'
The Star
20-05-2025
- Business
- The Star
Indian healthcare AI startup Qure.AI aiming for IPO in two years, CEO says
AI (Artificial Intelligence) letters are placed on computer motherboard in this illustration taken, June 23, 2023. REUTERS/Dado Ruvic/Illustration (Reuters) - an India-based startup providing artificial intelligence tools to healthcare firms, is aiming to turn profitable in the next financial year and for an initial public offer (IPO) in two years, its CEO told Reuters. The company, founded in 2016 and largely backed by AI firm Fractal Analytics, counts Peak XV Partners and Novo Nordisk's Novo Holdings among its investors, and has raised $125 million in funding so far, CEO Prashant Warier said. "We look to break even and be profitable next financial year. As we sort of get to that can start planning. And maybe in two-and-a-half years or two years is the earliest we can do an IPO," he said last week. He declined to elaborate on the firm's valuation. The firm was valued at $264 million as of November 2024, according to data from market intelligence platform Tracxn. provides AI solutions in diagnostics for early detection of tuberculosis, lung cancer and stroke risks. Its global clients include AstraZeneca, and Medtronic and Johnson and Johnson MedTech in India. The global market for AI in healthcare, valued at $14.92 billion in 2024, is expected to grow to $110 billion by 2030, according to market estimates. AI is being rapidly adopted by healthcare service providers around the world for early detection of diseases and to streamline work for overburdened professionals, according to industry experts. "We're growing at a rate of 60%-70% every year (in revenue) and I think we probably will accelerate in the next five years," Warier said, adding that they serve around 15 million patients annually. QureAI derives about 25% of revenue from the United States, which is its largest market, and is also eyeing expansion in the market with further partnerships, he said. The company also is focusing on on low-and middle-income countries in Latin America and Africa. India, however, is a much smaller market for the firm, contributing less than 5% of revenue. (Reporting by Rishika Sadam; Editing by Varun H K)
